Annual EBIT
-$6.53 M
+$5.96 M+47.73%
31 December 2022
Summary:
Nymox Pharmaceutical annual earnings before interest & taxes is currently -$6.53 million, with the most recent change of +$5.96 million (+47.73%) on 31 December 2022. During the last 3 years, it has risen by +$5.16 million (+44.14%).NYMX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$1.39 M
-$3.19 M-176.73%
31 March 2023
Summary:
Nymox Pharmaceutical quarterly earnings before interest & taxes is currently -$1.39 million, with the most recent change of -$3.19 million (-176.73%) on 31 March 2023.NYMX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$2.84 M
+$3.69 M+56.57%
31 March 2023
Summary:
Nymox Pharmaceutical TTM earnings before interest & taxes is currently -$2.84 million, with the most recent change of +$3.69 million (+56.57%) on 31 March 2023.NYMX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NYMX EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | +44.1% | +58.0% | +75.7% |
| 5 y5 years | +38.2% | +44.7% | +78.7% |
NYMX EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | +132.8% | -176.7% | -2928.5% |
Nymox Pharmaceutical EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2023 | - | -$1.39 M(-176.7%) | -$2.84 M(-56.6%) |
| Dec 2022 | -$6.53 M(-47.7%) | $1.80 M(-221.9%) | -$6.53 M(-41.3%) |
| Sept 2022 | - | -$1.48 M(-16.6%) | -$11.12 M(-14.0%) |
| June 2022 | - | -$1.78 M(-65.0%) | -$12.94 M(-14.6%) |
| Mar 2022 | - | -$5.08 M(+82.3%) | -$15.15 M(+21.2%) |
| Dec 2021 | -$12.50 M(+6.9%) | -$2.79 M(-15.5%) | -$12.50 M(+7.1%) |
| Sept 2021 | - | -$3.30 M(-17.2%) | -$11.67 M(-6.8%) |
| June 2021 | - | -$3.98 M(+64.1%) | -$12.53 M(+9.2%) |
| Mar 2021 | - | -$2.43 M(+23.9%) | -$11.47 M(-1.5%) |
| Dec 2020 | -$11.70 M(-10.9%) | -$1.96 M(-52.8%) | -$11.65 M(-4.5%) |
| Sept 2020 | - | -$4.16 M(+41.7%) | -$12.20 M(+15.6%) |
| June 2020 | - | -$2.93 M(+12.5%) | -$10.55 M(-17.7%) |
| Mar 2020 | - | -$2.61 M(+4.0%) | -$12.82 M(-2.4%) |
| Dec 2019 | -$13.12 M(+24.1%) | -$2.51 M(0.0%) | -$13.14 M(-1.4%) |
| Sept 2019 | - | -$2.51 M(-51.9%) | -$13.32 M(-2.2%) |
| June 2019 | - | -$5.21 M(+78.1%) | -$13.63 M(+25.7%) |
| Mar 2019 | - | -$2.92 M(+8.7%) | -$10.84 M(+2.5%) |
| Dec 2018 | -$10.58 M(-20.0%) | -$2.69 M(-4.3%) | -$10.58 M(-5.5%) |
| Sept 2018 | - | -$2.81 M(+16.1%) | -$11.19 M(-13.6%) |
| June 2018 | - | -$2.42 M(-9.0%) | -$12.94 M(-1.3%) |
| Mar 2018 | - | -$2.66 M(-19.4%) | -$13.12 M(-0.8%) |
| Dec 2017 | -$13.22 M(+2.7%) | -$3.30 M(-27.8%) | -$13.22 M(+4.0%) |
| Sept 2017 | - | -$4.57 M(+75.9%) | -$12.72 M(+13.6%) |
| June 2017 | - | -$2.60 M(-6.0%) | -$11.20 M(-9.5%) |
| Mar 2017 | - | -$2.76 M(-1.0%) | -$12.37 M(-3.9%) |
| Dec 2016 | -$12.88 M(-27.3%) | -$2.79 M(-8.4%) | -$12.88 M(-9.0%) |
| Sept 2016 | - | -$3.05 M(-19.2%) | -$14.15 M(-32.9%) |
| June 2016 | - | -$3.77 M(+15.4%) | -$21.08 M(-6.7%) |
| Mar 2016 | - | -$3.27 M(-19.6%) | -$22.60 M(+27.7%) |
| Dec 2015 | -$17.71 M(+284.6%) | -$4.07 M(-59.2%) | -$17.71 M(+24.8%) |
| Sept 2015 | - | -$9.98 M(+88.5%) | -$14.18 M(+189.2%) |
| June 2015 | - | -$5.29 M(-424.9%) | -$4.90 M(+1164.0%) |
| Mar 2015 | - | $1.63 M(-399.9%) | -$388.00 K(-91.6%) |
| Dec 2014 | -$4.60 M(-6.0%) | -$543.20 K(-22.1%) | -$4.60 M(-14.6%) |
| Sept 2014 | - | -$697.50 K(-10.2%) | -$5.39 M(-5.4%) |
| June 2014 | - | -$776.30 K(-70.0%) | -$5.69 M(-10.9%) |
| Mar 2014 | - | -$2.59 M(+94.7%) | -$6.39 M(+30.5%) |
| Dec 2013 | -$4.90 M(-35.7%) | -$1.33 M(+32.5%) | -$4.90 M(-23.4%) |
| Sept 2013 | - | -$1.00 M(-32.0%) | -$6.40 M(-3.5%) |
| June 2013 | - | -$1.47 M(+34.7%) | -$6.63 M(-3.5%) |
| Mar 2013 | - | -$1.09 M(-61.3%) | -$6.87 M(-9.8%) |
| Dec 2012 | -$7.62 M(-21.0%) | -$2.83 M(+129.5%) | -$7.61 M(+18.2%) |
| Sept 2012 | - | -$1.23 M(-28.1%) | -$6.44 M(-5.6%) |
| June 2012 | - | -$1.71 M(-6.7%) | -$6.82 M(-3.1%) |
| Mar 2012 | - | -$1.84 M(+10.9%) | -$7.04 M(-26.8%) |
| Dec 2011 | -$9.64 M(+47.7%) | -$1.66 M(+2.8%) | -$9.61 M(-4.0%) |
| Sept 2011 | - | -$1.61 M(-16.5%) | -$10.01 M(-0.4%) |
| June 2011 | - | -$1.93 M(-56.2%) | -$10.04 M(+2.9%) |
| Mar 2011 | - | -$4.41 M(+114.8%) | -$9.76 M(+49.4%) |
| Dec 2010 | -$6.53 M | -$2.05 M(+24.6%) | -$6.53 M(+8.5%) |
| Sept 2010 | - | -$1.65 M(+0.2%) | -$6.02 M(+5.0%) |
| June 2010 | - | -$1.65 M(+39.1%) | -$5.73 M(+8.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2010 | - | -$1.18 M(-23.3%) | -$5.30 M(+3.5%) |
| Dec 2009 | -$5.13 M(+10.7%) | -$1.54 M(+13.2%) | -$5.13 M(+13.9%) |
| Sept 2009 | - | -$1.36 M(+11.7%) | -$4.50 M(+0.3%) |
| June 2009 | - | -$1.22 M(+21.5%) | -$4.49 M(+1.9%) |
| Mar 2009 | - | -$1.00 M(+9.7%) | -$4.40 M(-4.9%) |
| Dec 2008 | -$4.63 M(-12.1%) | -$914.70 K(-32.2%) | -$4.63 M(-7.7%) |
| Sept 2008 | - | -$1.35 M(+18.6%) | -$5.02 M(-0.7%) |
| June 2008 | - | -$1.14 M(-7.6%) | -$5.05 M(-6.0%) |
| Mar 2008 | - | -$1.23 M(-5.5%) | -$5.37 M(+2.1%) |
| Dec 2007 | -$5.27 M(+9.0%) | -$1.30 M(-6.1%) | -$5.27 M(+1.7%) |
| Sept 2007 | - | -$1.39 M(-4.9%) | -$5.18 M(+3.2%) |
| June 2007 | - | -$1.46 M(+30.1%) | -$5.02 M(+2.3%) |
| Mar 2007 | - | -$1.12 M(-7.8%) | -$4.91 M(+1.5%) |
| Dec 2006 | -$4.83 M(+36.5%) | -$1.22 M(-0.9%) | -$4.83 M(+9.1%) |
| Sept 2006 | - | -$1.23 M(-8.6%) | -$4.43 M(+6.7%) |
| June 2006 | - | -$1.34 M(+28.0%) | -$4.15 M(+13.8%) |
| Mar 2006 | - | -$1.05 M(+29.1%) | -$3.65 M(+2.9%) |
| Dec 2005 | -$3.54 M(-2.0%) | -$813.00 K(-14.2%) | -$3.54 M(-0.9%) |
| Sept 2005 | - | -$947.40 K(+13.1%) | -$3.58 M(+7.9%) |
| June 2005 | - | -$837.80 K(-11.4%) | -$3.31 M(-8.2%) |
| Mar 2005 | - | -$945.60 K(+11.8%) | -$3.61 M(-0.2%) |
| Dec 2004 | -$3.61 M(-16.1%) | -$845.80 K(+23.5%) | -$3.62 M(-14.0%) |
| Sept 2004 | - | -$684.70 K(-39.6%) | -$4.20 M(-3.5%) |
| June 2004 | - | -$1.13 M(+18.8%) | -$4.36 M(+0.3%) |
| Mar 2004 | - | -$954.10 K(-33.4%) | -$4.35 M(+0.7%) |
| Dec 2003 | -$4.31 M(+26.4%) | -$1.43 M(+70.7%) | -$4.32 M(+14.7%) |
| Sept 2003 | - | -$839.30 K(-25.0%) | -$3.76 M(+1.0%) |
| June 2003 | - | -$1.12 M(+21.2%) | -$3.72 M(+7.2%) |
| Mar 2003 | - | -$923.60 K(+4.9%) | -$3.47 M(+1.8%) |
| Dec 2002 | -$3.41 M(+6.9%) | -$880.70 K(+10.0%) | -$3.41 M(-6.8%) |
| Sept 2002 | - | -$800.30 K(-7.8%) | -$3.66 M(+2.8%) |
| June 2002 | - | -$868.40 K(+0.9%) | -$3.56 M(+3.4%) |
| Mar 2002 | - | -$860.60 K(-23.8%) | -$3.44 M(+8.1%) |
| Dec 2001 | -$3.19 M(-21.8%) | -$1.13 M(+61.4%) | -$3.18 M(+3.5%) |
| Sept 2001 | - | -$699.60 K(-7.0%) | -$3.08 M(-7.1%) |
| June 2001 | - | -$752.20 K(+24.8%) | -$3.31 M(-13.9%) |
| Mar 2001 | - | -$602.90 K(-41.0%) | -$3.84 M(-5.6%) |
| Dec 2000 | -$4.08 M(+20.2%) | -$1.02 M(+9.3%) | -$4.07 M(+0.7%) |
| Sept 2000 | - | -$934.20 K(-27.3%) | -$4.05 M(+0.9%) |
| June 2000 | - | -$1.29 M(+54.6%) | -$4.01 M(+28.4%) |
| Mar 2000 | - | -$831.70 K(-16.3%) | -$3.12 M(-6.3%) |
| Dec 1999 | -$3.39 M(-28.9%) | -$994.00 K(+10.5%) | -$3.33 M(-7.5%) |
| Sept 1999 | - | -$899.30 K(+126.0%) | -$3.60 M(-7.8%) |
| June 1999 | - | -$398.00 K(-61.8%) | -$3.91 M(-13.4%) |
| Mar 1999 | - | -$1.04 M(-17.7%) | -$4.51 M(-1.3%) |
| Dec 1998 | -$4.77 M(+37.2%) | -$1.27 M(+5.2%) | -$4.57 M(+14.7%) |
| Sept 1998 | - | -$1.20 M(+20.2%) | -$3.98 M(+8.2%) |
| June 1998 | - | -$1.00 M(-9.0%) | -$3.68 M(+5.8%) |
| Mar 1998 | - | -$1.10 M(+61.6%) | -$3.48 M(+52.6%) |
| Dec 1997 | -$3.48 M | -$680.30 K(-24.4%) | -$2.28 M(+42.5%) |
| Sept 1997 | - | -$899.80 K(+12.5%) | -$1.60 M(+128.6%) |
| June 1997 | - | -$799.80 K(-897.4%) | -$699.50 K(-797.4%) |
| Mar 1997 | - | $100.30 K | $100.30 K |
FAQ
- What is Nymox Pharmaceutical annual earnings before interest & taxes?
- What is the all time high annual EBIT for Nymox Pharmaceutical?
- What is Nymox Pharmaceutical quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Nymox Pharmaceutical?
- What is Nymox Pharmaceutical TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Nymox Pharmaceutical?
What is Nymox Pharmaceutical annual earnings before interest & taxes?
The current annual EBIT of NYMX is -$6.53 M
What is the all time high annual EBIT for Nymox Pharmaceutical?
Nymox Pharmaceutical all-time high annual earnings before interest & taxes is -$2.81 M
What is Nymox Pharmaceutical quarterly earnings before interest & taxes?
The current quarterly EBIT of NYMX is -$1.39 M
What is the all time high quarterly EBIT for Nymox Pharmaceutical?
Nymox Pharmaceutical all-time high quarterly earnings before interest & taxes is $1.80 M
What is Nymox Pharmaceutical TTM earnings before interest & taxes?
The current TTM EBIT of NYMX is -$2.84 M
What is the all time high TTM EBIT for Nymox Pharmaceutical?
Nymox Pharmaceutical all-time high TTM earnings before interest & taxes is $100.30 K